iTeos Therapeutics (ITOS) AI Stock Analysis

• Market Cap: $297.39M
• Dividend Yield: N/A
• Average Volume (3M): 484.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: N/A
• EPS Growth: 14.60%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 56
• Industry: Biotechnology
• EPS (TTM): -3.23
• Shares Outstanding: 38,273,796
• 10 Day Avg. Volume: 626,536
• 30 Day Avg. Volume: 484,279
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.62
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $23.00
• Price Target Upside: 196.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

iTeos Therapeutics has a low overall stock score of 45.0, primarily due to significant financial performance issues, including stagnant revenue and declining profitability, compounded by negative cash flows. While technical analysis shows some short-term positive momentum, long-term indicators and valuation metrics are less favorable. The absence of positive earnings and dividends diminishes its attractiveness to investors.

Positive Factors

Clinical Trials

The potential for upside is seen from large clinical updates from the company’s anti-TIGIT belrestotug therapies in NSCLC and SCCHN, which could positively impact the stock.

Financial Position

The company's strong cash position of approximately $655 million is expected to provide financial runway through 2027, ensuring operational stability.

Pipeline Growth

The company's catalyst-rich pipeline with expected data updates from multiple clinical studies in 2025 could drive future growth and investor interest.

Negative Factors

Clinical Trial Concerns

Interim data from a study showed a high occurrence of treatment-related adverse events, leading to amendments in the study protocol to address safety concerns.

Competitive Landscape

The bar is high for belrestotug + dostarlimab +/- nelistrotug in PD-L1+ 1L rmHNSCC, as petosemtamab has set a high benchmark with an ORR of ~67%, posing a competitive challenge.

Financial Performance

The company reported no revenue and a net loss, highlighting financial challenges with projections indicating continued losses in the future.

iTeos Therapeutics Business Overview & Revenue Model

Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

iTeos Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include potential milestone payments and royalties from partnerships and collaborations with larger pharmaceutical companies. A significant partnership with GlaxoSmithKline (GSK) involves the development and commercialization of EOS-448, an anti-TIGIT antibody, which provides upfront payments, potential milestone payments, and future royalties on sales. Additionally, the company may generate revenue through licensing agreements and strategic collaborations, leveraging its expertise in immuno-oncology to expand its financial opportunities.

iTeos Therapeutics Financial Statement Overview

Summary

iTeos Therapeutics faces significant financial challenges. The income statement reflects stagnant revenue and declining profitability, leading to a score of 28.0. The balance sheet is relatively strong with a high equity ratio but shows declining assets and cash reserves, resulting in a score of 52.0. Cash flow issues are critical, with negative operating and free cash flows, scoring 40.0. Overall, financial performance is weak, with a need for improved revenue and cost management strategies.

Income Statement

iTeos Therapeutics has experienced significant volatility in its revenue and profitability. The TTM (Trailing-Twelve-Months) data shows a severe decline in profitability, with negative EBIT and net income margins. Revenue growth is stagnant, as current revenue matches the previous period. These trends reflect challenges in generating consistent revenue and managing costs, which is critical for long-term sustainability.

Balance Sheet

The balance sheet reveals a strong equity base, with a high equity ratio indicating stability. However, the debt-to-equity ratio is low, which is positive, though offset by declining total assets and stockholders' equity over recent periods. Despite these strengths, the decrease in cash reserves and equity suggests potential challenges in maintaining financial health if current trends continue.

Cash Flow

The cash flow situation is concerning with negative operating and free cash flows, indicating struggles in generating cash from operations. The free cash flow growth rate is negative, highlighting a worsening trend. Despite a positive financing cash flow, reliance on external funding is not a sustainable strategy for cash flow management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.00M	12.60M	267.63M	344.77M	0.00
	Gross Profit
33.76M	11.70M	266.82M	344.16M	-535.00K
	EBIT
-159.53M	-151.10M	126.32M	244.90M	-45.24M
	EBITDA
-159.53M	-151.10M	148.38M	257.08M	-37.84M
	Net Income Common Stockholders
-134.41M	-112.64M	96.65M	214.52M	-38.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
494.65M	531.92M	613.16M	848.54M	336.33M
	Total Assets
686.98M	667.59M	754.99M	884.71M	344.56M
	Total Debt
5.10M	6.06M	4.67M	5.34M	0.00
	Net Debt
-137.03M	-245.12M	-280.13M	-843.20M	-336.33M
	Total Liabilities
96.68M	92.36M	91.66M	331.89M	21.36M
	Stockholders Equity
590.29M	575.23M	663.33M	552.82M	323.20M
Cash Flow		Free Cash Flow
-99.81M	-106.72M	-112.13M	511.96M	-25.53M
	Operating Cash Flow
-98.18M	-103.76M	-111.19M	513.14M	-25.18M
	Investing Cash Flow
-131.15M	72.66M	-446.06M	-1.24M	-377.00K
	Financing Cash Flow
122.24M	1.11M	1.98M	3.66M	340.34M

iTeos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITOS, the sentiment is Positive. The current price of 7.77 is above the 20-day moving average (MA) of 6.43, above the 50-day MA of 6.68, and below the 200-day MA of 9.71, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 64.58 is Neutral, neither overbought nor oversold. The STOCH value of 91.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITOS.

iTeos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%
CDTX	51 Neutral	$237.58M	―	-222.36%	―	-86.28%	-476.70%
ABEO	50 Neutral	$320.13M	―	-216.57%	―	-100.00%	30.33%
MNPR	48 Neutral	$274.82M	―	-51.42%	―	―	-35.23%
AVIR	47 Neutral	$254.87M	―	-33.88%	―	―	-22.66%
DSGN	47 Neutral	$263.97M	―	-19.08%	―	―	26.63%
ITOS	45 Neutral	$297.39M	―	-23.68%	―	―	14.60%

iTeos Therapeutics Corporate Events

iTeos Therapeutics Plans 2025 Data Presentation on Therapies

iTeos Therapeutics announced plans to present new data from its clinical trials and research pipeline in 2025, focusing on its TIGIT:PD-1 therapies. The company aims to enhance its market opportunities and improve the safety profile of its therapies, with a financial runway secured through 2027. Key data readouts are anticipated from ongoing trials, including GALAXIES Lung-201 and GALAXIES H&N-202, while collaborations with GSK are expected to further bolster iTeos’ position in the immuno-oncology landscape.